Beam Therapeutics (BEAM) FCF Margin (2019 - 2026)

Beam Therapeutics (BEAM) has reported FCF Margin for 8 consecutive years, with 411.95% the latest figure, recorded in Q1 2026.

• In Q1 2026, FCF Margin rose 101976.0% year-over-year to 411.95%; the TTM figure through Mar 2026 stood at 225.7% (up 32928.0% YoY), while the FY2025 annual figure was 247.86%, up 30014.0% from the prior year.
• FCF Margin declined to 411.95% in Q1 2026 per BEAM's latest filing, from 71.37% in the prior quarter.
• Across five years, FCF Margin topped out at 2409.68% in Q1 2022 and bottomed at 1431.71% in Q1 2025.
• Historically, FCF Margin has averaged 413.59% across 5 years, with a median of 501.33% in 2023.
• Annual changes were most pronounced in 2022 — FCF Margin surged 99979131 bps — and 2023, when it tumbled 288816 bps.
• Beam Therapeutics' FCF Margin stood at 386.54% in 2022, then soared by 113 bps to 51.81% in 2023, then tumbled by 593 bps to 255.26% in 2024, then jumped by 72 bps to 71.37% in 2025, then slumped by 477 bps to 411.95% in 2026.
• Business Quant data shows BEAM's FCF Margin at 411.95% in Q1 2026, 71.37% in Q4 2025, and 808.46% in Q3 2025.